XML 26 R71.htm IDEA: XBRL DOCUMENT v2.4.0.8
Note 16 - Commitments and Contingencies (Details)
 3 Months Ended 9 Months Ended 1 Months Ended 3 Months Ended 80 Months Ended 13 Months Ended 3 Months Ended 9 Months Ended 1 Months Ended
Sep. 30, 2014
USD ($)
Sep. 30, 2013
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2013
USD ($)
Dec. 31, 2013
USD ($)
Sep. 30, 2014
ANP [Member]
Agreements With a Chinese Governmental Entity [Member]
USD ($)
Nov. 30, 2012
Agreements With a Chinese Governmental Entity [Member]
Land-Use Rights [Member]
USD ($)
Jan. 31, 2010
Agreements With a Chinese Governmental Entity [Member]
Land-Use Rights [Member]
USD ($)
Nov. 30, 2012
Agreements With a Chinese Governmental Entity [Member]
USD ($)
May 31, 2005
Exclusive Marketing Rights for Enoxaparin [Member]
Andrx Pharmaceuticals, Inc. [Member]
USD ($)
Jan. 31, 2012
Exclusive Marketing Rights for Enoxaparin [Member]
Watson Pharmaceuticals, Inc. [Member]
Sep. 30, 2014
Exclusive Marketing Rights for Enoxaparin [Member]
Watson Pharmaceuticals, Inc. [Member]
USD ($)
Dec. 31, 2011
Exclusive Marketing Rights for Enoxaparin [Member]
Watson Pharmaceuticals, Inc. [Member]
USD ($)
Dec. 31, 2013
Exclusive Marketing Rights for Enoxaparin [Member]
Watson Pharmaceuticals, Inc. [Member]
USD ($)
Jan. 31, 2013
Exclusive Marketing Rights for Enoxaparin [Member]
Actavis, Inc. [Member]
Sep. 30, 2014
Land-Use Rights [Member]
USD ($)
Dec. 31, 2013
Land-Use Rights [Member]
USD ($)
Jul. 31, 2014
Insuling Supply Agreement With MannKind [Member]
USD ($)
Jul. 31, 2014
Insuling Supply Agreement With MannKind [Member]
EUR (€)
Sep. 30, 2014
Research and Development Arrangement [Member]
USD ($)
Sep. 30, 2014
Minimum [Member]
Sep. 30, 2014
Maximum [Member]
Sep. 30, 2014
Commitments to Purchase Equipment and Raw Materials [Member]
USD ($)
Jul. 31, 2014
MannKind Corporation [Member]
Note 16 - Commitments and Contingencies (Details) [Line Items]                                                
Proceeds from Customers                   $ 4,500,000                            
Deferred Revenue, Additions                   4,500,000                            
Recognition of Deferred Revenue                         0                      
Deferred Revenue, Period for Recognition                     7 years                          
Distribution Agreement With Corporate Partner, Renewal Option Period                       3 years     3 years                  
Deferred Revenue                       2,800,000   3,300,000       14,000,000 11,000,000          
Supply Commitment, Remaining Minimum Amount Committed                                   152,300,000 120,100,000          
Long-term Supply Commitment, Optional Renewal Period                                               2 years
Lessee Leasing Arrangements, Operating Leases, Renewal Term                                         1 year 6 years    
Operating Leases, Rent Expense 800,000 800,000 2,300,000 2,400,000                                        
Long-term Purchase Commitment, Amount                                             7,700,000  
Investments in and Advance to Affiliates, Subsidiaries, Associates, and Joint Ventures           41,000,000                                    
Registered Capital Commitment to Subsidiary           61,000,000                                    
Contractual Obligation 14,740,000   14,740,000     20,000,000     15,000,000                              
Finite-Lived Intangible Assets, Gross 30,491,000   30,491,000   30,496,000   1,300,000 1,200,000               2,540,000 2,540,000              
Purchase Commitments Amount Fulfilled                                       $ 3,200,000